New targeted therapy effective in treating advanced prostate cancer

[Guest guest]

An experimental drug is showing promise for the treatment of men with

an aggressive form of advanced prostate cancer. A new multicenter study

has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer (CRPC), known for

its poor prognosis and limited treatment options. The research, led by investigators at Memorial Sloan-Kettering Cancer Center, appears early online and in an upcoming edition of The Lancet.

According to the findings of the Phase 1-2 study, MDV3100 not only shrank patients' tumors, but also reduced serum levels of the tumor marker prostate-specific antigen (PSA), stabilized disease that had spread to soft tissues and the bone, and reduced the number of circulating tumor cells in the blood....Click on the below link for the full story:<http://www.urotoday.com/61/browse_categories/prostate_cancer/new_targeted_therapy_effective_in_treating_advanced_prostate_cancer04152010.html>You're welcome to browse within the

above medical web site, but

you'll be requested to

register, which you can safely do. Non-doctors are welcome and there's never any spam.